Ramy Farid - 30 May 2025 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Issuer symbol
VIR
Transactions as of
30 May 2025
Net transactions value
$0
Form type
4
Filing time
02 Jun 2025, 19:19:23 UTC
Previous filing
04 Mar 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Farid Ramy Director C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO /s/ Vanina de Verneuil, Attorney-In-Fact 02 Jun 2025 0001797707

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +8,000 +50% $0.000000 24,000 30 May 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +16,000 $0.000000 16,000 30 May 2025 Common Stock 16,000 $4.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2 The RSUs will vest in full on May 30, 2026.
F3 The shares subject to the stock option will vest and become exercisable in full on May 30, 2026.